HomeCompareCAWLF vs ABBV

CAWLF vs ABBV: Dividend Comparison 2026

CAWLF yields 7.92% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $68.5K in total portfolio value
10 years
CAWLF
CAWLF
● Live price
7.92%
Share price
$0.13
Annual div
$0.01
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$33.8K
Annual income
$1,308.52
Full CAWLF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — CAWLF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCAWLFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CAWLF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CAWLF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CAWLF
Annual income on $10K today (after 15% tax)
$673.53/yr
After 10yr DRIP, annual income (after tax)
$1,112.24/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $19,943.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CAWLF + ABBV for your $10,000?

CAWLF: 50%ABBV: 50%
100% ABBV50/50100% CAWLF
Portfolio after 10yr
$68.1K
Annual income
$13,040.14/yr
Blended yield
19.16%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CAWLF
No analyst data
Altman Z
1.9
Piotroski
6/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CAWLF buys
0
ABBV buys
0
No recent congressional trades found for CAWLF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCAWLFABBV
Forward yield7.92%3.06%
Annual dividend / share$0.01$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$33.8K$102.3K
Annual income after 10y$1,308.52$24,771.77
Total dividends collected$10.5K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CAWLF vs ABBV ($10,000, DRIP)

YearCAWLF PortfolioCAWLF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,492$792.39$11,550$430.00$58.00ABBV
2$13,148$851.07$13,472$627.96$324.00ABBV
3$14,978$909.98$15,906$926.08$928.00ABBV
4$16,996$968.84$19,071$1,382.55$2.1KABBV
5$19,213$1,027.40$23,302$2,095.81$4.1KABBV
6$21,643$1,085.45$29,150$3,237.93$7.5KABBV
7$24,301$1,142.76$37,536$5,121.41$13.2KABBV
8$27,201$1,199.15$50,079$8,338.38$22.9KABBV
9$30,360$1,254.46$69,753$14,065.80$39.4KABBV
10$33,793$1,308.52$102,337$24,771.77$68.5KABBV

CAWLF vs ABBV: Complete Analysis 2026

CAWLFStock

CWC Energy Services Corp., a contract drilling and well servicing company, provides oilfield services to oil and gas exploration and production companies in Canada and the United States. The company operates through two segments, Contract Drilling and Production Services. It also provides completion, maintenance, workover, and well decommissioning services; and equipment and related services. The company operates through a fleet of 144 service rigs; 75 single, 55 double, and 14 slant rigs; 10 electric triple drilling rigs with depth ratings from 3,600 to 7,600 meters; and 9 telescopic double drilling rigs with depth ratings from 3,200 to 5,000 meters. The company was formerly known as CWC Well Services Corp. and changed its name to CWC Energy Services Corp. in May 2014. CWC Energy Services Corp. is headquartered in Calgary, Canada.

Full CAWLF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CAWLF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CAWLF vs SCHDCAWLF vs JEPICAWLF vs OCAWLF vs KOCAWLF vs MAINCAWLF vs JNJCAWLF vs MRKCAWLF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.